	Multimodal plasma and urinary cell-free DNA profiling improves risk stratification in newly diagnosed prostate cancer. NPJ Precis Oncol Riediger AL, Eickelschulte S, Janke F, Janscho D, Lazareva O, Hübschmann D, Duensing S, Stegle O, Sültmann H, Görtz M. PMID: 41772128 [PubMed - as supplied by publisher]
	Benchmarking multiple instance learning architectures from patches to pathology for prostate cancer detection and grading using attention-based weak supervision. Sci Rep Butt NA, Sarwat D, Noya ID, Tutusaus K, Samee NA, Ashraf I. PMID: 41771952 [PubMed - as supplied by publisher]
	Risk of childhood and adolescent, and young adult cancer in offspring of men with testicular cancer: A Danish nationwide study. Int J Cancer Bandak M, Rosthøj S, Aalborg GL, Lauritsen J, Giwercman A, Haugnes HS, Daugaard G, Jensen A. PMID: 41771671 [PubMed - as supplied by publisher]
	When is immunotherapy too much? The case of favorable-risk metastatic renal cell carcinoma. Crit Rev Oncol Hematol Buti S, Valle BD, Acunzo A, Tuttobene P, Tamarozzi P, Agnetti V, Maffezzoli M, Banna GL, Corradi D, Santoni M. PMID: 41771460 [PubMed - as supplied by publisher]
	Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol Necchi A, Maiorano BA, de Jong JJ, Proudfoot JA, Basile G, Cigliola A, Mercinelli C, Tateo V, Piacentini M, Pastorino G, Latini G, Tomasi E, Davicioni E, Moschini M, Brembilla G, Colecchia M, de Cobelli F, Briganti A, Ross JS, Pavlick DC, Montorsi F. PMID: 41771275 [PubMed - as supplied by publisher]
	Single cell and multi-omics analysis reveal senescence-related molecular subtypes and a prognostic signature in clear cell renal cell carcinoma. Discov Oncol Wang J, Kong W, Shao W, Yu Z, Liu H, Gao Z, Liu Y, Zhao Y, Tao L, Zhang M, Liang C. PMID: 41770477 [PubMed - as supplied by publisher]
	Metastatic prostate cancer in the genomic era: Guideline-concordant strategies for diagnosis, treatment, and survivorship. J Am Assoc Nurse Pract Connors LM. PMID: 41770148 [PubMed - in process]
	Metastatic Clear Cell Renal Cell Carcinoma Identified in a Gastric Biopsy: Diagnostic Recognition in an Unusual Site. Cureus Nikolaus Y, Sigdel S. PMID: 41769517 [PubMed]
	Inhibition of Castration-Sensitive LNCaP, Castration-Resistant TRAMP-C2, and Bone-Metastatic C4-2B Prostate Cancer Cell Growth by an Alpha-Tomatine Tomato Extract: In Vitro and In Vivo Study. Cureus Takeda S, Uehara M, Yurube T, Ueda S, Shigemura K. PMID: 41769483 [PubMed]
	Discrepancies Between Global Consensus and Local Implementation in the Management of Advanced Prostate Cancer. Eur Urol Open Sci Mehra N, Oprea-Lager DE, van de Luijtgaarden ACM, van der Voort van Zyp JRN, Aluwini S, Stoevelaar HJ, van den Bergh RCN, APCCC-NL panel. PMID: 41768772 [PubMed]
	Identifying Prognostic Biomarkers and Key Pathways in Renal Clear Cell Carcinoma: A Pilot Study Using Integrated miRNA and Gene Expression Analysis. Biochem Res Int Manoochehri H, Mirzaee K, Taherkhani A, Gholyaf M. PMID: 41768422 [PubMed]
	Computational pathology in bladder cancer: A scoping review. Bladder Cancer Superdock M, Wobker SE, Carmicheal I, Kim WY. PMID: 41768416 [PubMed]
	KLS-3021, a multifunctional oncolytic virus, demonstrates potent early-intervention efficacy in preclinical models of prostate-confined and locally advanced prostate cancer. Front Oncol Seo J, Park K, Lee S, Kang H, Kim J, Lee E, Shin J, Hong SO, Kim S, Kim SJ. PMID: 41768263 [PubMed]
	The diagnostic value of radiomics-based machine learning for lymph node metastasis in prostate cancer: a systematic review and meta-analysis. Front Oncol Liu Z, Yang Y, Guan X. PMID: 41768254 [PubMed]
	Machine learning approaches for predicting progression in hormone-sensitive prostate cancer patients. Front Oncol Zhu B, Jiang H, Zhang C, Wang Q, Yang L, Yang H, Li R, Li J, Pang X, Zheng Y, Yan L, Wang Y, Bai Y. PMID: 41768252 [PubMed]
	Exploring treatment models for oligometastatic castration-sensitive prostate cancer: evolution of therapeutic strategies. Front Oncol Xu H, Guo J, Peng W, Wang J, Shi L, Yang X. PMID: 41768233 [PubMed]
	Low yield of pathological lymph node metastasis among patients with invasive penile squamous cell carcinoma in the context of high HIV burden: evidence from a prospective cohort study in Zambia. Front Urol Mapulanga V, Ngalamika O, Mumba C, Muhimbe Z, Pettaway CA, Bowa K, Sinkala E. PMID: 41767588 [PubMed]
	Clinically oriented immune heterogeneity in prostate cancer: emerging targets and strategies. Front Immunol Zhan M, Zhao B, Wu J, Li K, Chen Y, Chen H, Zhao L, Zhu J. PMID: 41766852 [PubMed - in process]
	Management of Advanced Prostate Cancer in the Asia-Pacific Region: Summary of the Asia-Pacific Advanced Prostate Cancer Symposium 2025. Asia Pac J Clin Oncol Chiong E, Eapen R, Buchan N, Chen K, Hakim L, Hamid AR, Joung JY, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Mallick I, Ng CF, Ngam PI, Ong TA, Pang J, Poon DMC, Roberts N, Saad M, Sakamoto S, Tey J, Thang SP, Toh PC, Türkeri L, Vinh NT, Wong A, Zhu Y, ANZUP Cancer Trials Group, Davis ID. PMID: 41766356 [PubMed - as supplied by publisher]
	Integrated scRNA-seq and bulk transcriptomics identify an amino acid metabolism-associated prognostic signature and highlight FUS as a potential driver in prostate cancer progression. Funct Integr Genomics Yuan J, Shen D, Pan Z, Lv F, Zhao Y, Zheng W, Yin Q, Wu L, Yu J, Xu C, He Q, Pan H. PMID: 41766003 [PubMed - in process]

Articles 1 - 20 / 176391

Page 1 of 8820



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy